Novartis, Dana-Farber seek to bar generic leukaemia drug
Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.
Senators urge USPTO to curb ‘patent thicket’ abuse
A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.
Pfizer sues MSN Labs over Xeljanz generic
Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.
Arbutus, Genevant reject Moderna’s vaccine patent defence
Moderna’s bid to avoid a COVID-19 patent claim has been rejected by two pharma companies that are suing the vaccine manufacturer for infringing its drug delivery technology.
California judge approves BMS $10.8m settlement
A judge at the US District Court for the Northern District of California has granted a motion for preliminary approval of a $10.8 million settlement in an antitrust suit.
Illumina urges court to overturn DNA patent verdict
Biotech company Illumina has asked a Delaware court to overturn a finding that it willfully infringed two DNA sequencing patents and must pay $334 million in damages.
GSK bets $2.1bn on Boston-based biopharma company
GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.
J&J units launch prostate cancer drug suit
Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.
Pfizer commits to offer drugs not-for-profit to 45 low-income countries
Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
UK regulators no longer exempt from paying successful parties' costs
The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
